Clora

The best place to discover, build, and manage on-demand life science teams.

[Clora @MeetClora]

Hear Clora CEO @rahulc speak with @AcadiaPharma CEO Catherine Owen Adams about her journey to #biotech #leadership, the future of CNS #innovation, and the forces shaping biotech today. Listen to the full episode.

[Biotech2050 Podcast @Biotech2050Pod]

How do you go from pharmacist to leading a billion-dollar biotech? Catherine Owen Adams, CEO of @AcadiaPharma, joins @rahulc on #Biotech2050 to discuss neuro & rare disease innovation, commercialization, AI, & first-time CEO lessons. 🧠 🎙️- https://t.co/y36mZmKYFB

[Clora @MeetClora]

Our new website is live: https://t.co/EE4VoCB2mM

15,000+ vetted life sciences consultants. Access in days, not months. Faster than hiring. More flexible than CROs.

#Biotech #LifeSciences

[Clora @MeetClora]

Proud to support our client @C4Therapeutics as they advance targeted #proteindegradation. They just announced an expanded long-term partnership with @Roche, highlighting strong momentum behind their platform. Read more:
https://t.co/5VUoou4uoh

[Clora @MeetClora]

Biotech doesn’t have a hiring problem—it has a #resourcing strategy problem.

Only 48% of talent needs are met, while specialized roles take 100+ days to fill. Leading companies are rethinking work, bringing in #expertise on demand and prioritizing flexibility to stay on track.

[Clora @MeetClora]

In #biotech and #pharma, speed has been seen as a tradeoff with quality—but that’s changing. Progress now depends on fast access to the right #expertise. Leading teams use agile #talent models to tap global experts on demand, accelerating timelines without compromising rigor.

[Clora @MeetClora]

Which #resourcing model gives you speed, control, and quality? FTEs take 100+ days. CROs lack flexibility. See how #consultants deliver expertise without delays. Download our free reports to compare your options: https://t.co/f96wYCO9yn

[Clora @MeetClora]

Clora CEO @rahulc speaks with physician-scientist and #biotech founder Sheila Gujrathi, MD, about her path through biotech #leadership, building companies, and the lessons she’s learned along the way. Listen to the #podcast now.

[Biotech2050 Podcast @Biotech2050Pod]

This episode is sponsored by @Quartzy.
Sheila Gujrathi, MD joins @rahulc on #Biotech2050 to discuss leadership, venture building, & lessons from her book The Mirror Effect on confidence, leadership & navigating power in biotech
🎧 https://t.co/JRceKwL7KY
#TheMirrorEffect #biotech

[Clora @MeetClora]

Biotech #IPOs may be making a comeback in 2026. After peaking with 87 U.S. #biotech IPOs in 2021, activity dropped to just 11 in 2025. Now momentum may be returning as more companies begin entering the public markets: https://t.co/ha2W2bBW8Q

[Clora @MeetClora]

JPM 2026 signaled renewed optimism for #biopharma. Deals are expected to center on late-stage pipelines/assets, while R&D priorities move toward more prevalent diseases over rare/orphan indications. Read more from @BioSpace: https://t.co/IxDSEmGVbl

[Clora @MeetClora]

.@bainalerts highlights 4 trends reshaping deal strategy: vertical integration for speed and control, next-gen obesity assets, continued momentum in ADCs, & growing cross-border opportunity in Greater China. Differentiation—not scale—is driving M&A: https://t.co/WwKeVCo319

[Clora @MeetClora]

Biopharma leaders from @Perspective_Tx, @LineageCell and Catalyst #Pharma are optimistic about 2026. Investment is returning, #science is strong, and momentum is building after a tough 2025. Read more from @FiercePharma: https://t.co/BrEbX9BSzF

[Clora @MeetClora]

Big congrats to our client, Parabilis Medicines, on closing a $305M Series F to advance their Helicon™ medicines, including a Phase 3 trial for FOG-001 in desmoid tumors. A big move in targeting tough-to-treat cancers. Read more in their press release: https://t.co/OlaYyyZTvG

[Clora @MeetClora]

We’re proud to support our client as Somite becomes @CellularIntelHQ, building the first universal virtual cell-signaling model to guide, not just map, #biology. A bold step toward predictive, programmable #cellbehavior.

[Micha Breakstone @MichaBreakstone]

Somite is now Cellular Intelligence.

More than a rebrand, this reflects what our team has been building over the last two years: the first universal virtual cell signaling model, designed to understand, predict, and ultimately control cell behavior.

To further mark this step forward, we’re releasing a new white paper that shares our technical progress and maps out what is to come: https://t.co/UM1G1cDZpp

Deeply proud of our team for daring to turn an implausible idea into reality. Dive into what we’re creating at @CellularIntelHQ today: https://t.co/0u6GSYz5F7

[Clora @MeetClora]

Will you be in the Bay Area for #JPM2026 next week?

Our CEO @rahulc will be there and would love to connect. Learn how #Clora is helping #lifesciences companies advance programs faster without the long-term cost of traditional #hiring.

Drop a comment to set up a meeting!

[Clora @MeetClora]

As we close out the year, we want to extend our gratitude to the life science professionals and companies we’ve had the privilege to work with.

Thank you for making 2025 a year of innovation, collaboration, and growth.

Wishing you a joyful holiday season and a Happy New Year.

[Clora @MeetClora]

Will you be in the Bay Area during #JPM2026 next month?

Meet with our CEO @rahulc to learn how #Clora is helping companies accelerate development without the capital commitment of traditional #hiring.

Request a meeting in the comments below or send us a message.

[Clora @MeetClora]

New @Biotech2050Pod episode: Clora CEO @rahulc talks with John Lepore, CEO of @ProFoundTx, on leading in #biotech, uncovering the human proteome, and using #AI to unlock new drug targets. A look into the next frontier of #medicine. Listen using the link below.

[Biotech2050 Podcast @Biotech2050Pod]

The episode is sponsored by @Quartzy.
🔬 “What if we’ve only mapped a fraction of human proteins?”
@rahulc interviews John Lepore, CEO of @ProFoundTx, on AI, risk-taking, & the next frontier of first-in-class medicines powered by the expanded proteome.
🎧 https://t.co/4g8eX9oD6v

[Clora @MeetClora]

Biotech VC funding jumped 70.9% in Q3 2025, from $1.8B to $3.1B. Series D saw the biggest leap, up nearly 60x to $832M, a strong signal of renewed investor confidence amid ongoing challenges. Read more: https://t.co/DtLCT3INkO

#biotech #venturecapital #biotechfunding

[Clora @MeetClora]

.@pfizer's $10B+ deal to acquire @MetseraInc is a major #biotech M&A move, signaling renewed #bigpharma investment. Despite ongoing industry challenges, momentum in M&A and licensing is building. Read more: https://t.co/Reyy8ZOaPi

[Clora @MeetClora]

🎙️ @JTananbaum, CEO of @ForesiteCapital, joins Clora CEO @rahulc to explore #biotech innovation, #AI in #drugdiscovery, and investing through market cycles. A must-listen on strategy, #science, and impact. Listen using the link below.

[Biotech2050 Podcast @Biotech2050Pod]

💸 Interest rates 🤖 AI 🧠 Human insight
All shaping the future of biotech.
🎙️ @JTananbaum, Founder & CEO of @foresitecapital, joins @rahulc on #Biotech2050 to unpack venture cycles, AI’s rise in drug discovery, & next wave of innovation.
🎧 Listen now →https://t.co/5n6uSVZnEz